• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Nordic journal of psychiatry. >What is the evidence for the use of second-generation antipsychotic long-acting injectables as maintenance treatment in bipolar disorder?
【24h】

What is the evidence for the use of second-generation antipsychotic long-acting injectables as maintenance treatment in bipolar disorder?

机译：在躁郁症中使用第二代抗精神病长效注射剂作为维持治疗的证据是什么？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: In recent years, the use of second-generation antipsychotics long-acting injectable in the maintenance treatment of bipolar disorder has sparked interest in improving adherence and reducing the risk of relapse. Aims: This report aims to review the available evidence concerning the use of second-generation antipsychotics depot in bipolar disorder and specify the typology of patients that could be eligible for this formulation. Methods: A systematic review of the literature was conducted using Pubmed and EMBASE. Results: Data available for the clinician assessing the interests of second-generation antipsychotics depot in long-term treatment of bipolar disorder are limited to risperidone. It seems particularly relevant for bipolar patients with poor adherence or early in the course of illness and can be used as monotherapy with manic polarity. It should always be considered for use in combination with at least one other mood stabilizer in patients with depressive polarity. As for other medications, the benefit/risk ratio for a long-acting should be evaluated individually. Conclusions: If using a depot formulation could be considered for all patients in order to approach a perfect compliance, patients with certain clinical profiles could be an argument for prioritizing the use of long-acting injectable as maintenance treatment. Additional studies are needed with other second-generation antipsychotics depot in bipolar patients to generalize their use in the maintenance treatment of bipolar disorder but the future golden standard of studies with long-acting formulations remains to be defined.
机译：背景：近年来，在躁郁症的维持治疗中使用第二代抗精神病药长效注射剂引起了人们对改善依从性和降低复发风险的兴趣。目的：本报告旨在回顾有关在躁郁症中使用第二代抗精神病药库的现有证据，并详细说明可能适合该制剂的患者类型。方法：使用Pubmed和EMBASE对文献进行系统的综述。结果：临床医生评估第二代抗精神病药库长期治疗躁郁症的兴趣的数据仅限于利培酮。对于依从性差或病程较早的双相型患者，这似乎特别相关，可以用作躁狂极性的单药治疗。对于抑郁症极性患者，应始终考虑将其与至少一种其他情绪稳定剂联合使用。至于其他药物，长效的获益/风险比应单独评估。结论：如果可以考虑对所有患者使用长效制剂以达到完美的依从性，则具有某些临床特征的患者可能是优先考虑使用长效注射剂作为维持治疗的论点。双相情感障碍患者的其他第二代抗精神病药库需要进一步研究，以推广其在双相情感障碍维持治疗中的应用，但长效制剂的未来研究黄金标准仍有待确定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号